Running Successful NSCLC clinical trials: Epidemiology, Challenges and Solutions
There have been significant advances in our understanding and treatment of this disease over the past century, particularly for non-small cell lung cancer (NSCLC). New diagnostic and therapeutic approaches are appearing, and with new drugs becoming available every year, we have seen improvement in survival rate and quality of life. However, there are many questions that remain to be answered, and they could impact the success of your upcoming NSCLC trial.
NSCLC Clinical Trials: History, Trends, and Opportunities offers insights on overcoming several major challenges of these studies based on PSI CRO’s experience with more than 25 Phase 2 and 3 clinical trials in advanced and metastatic NSCLC during the past ten years. Download the new white paper to learn about:
- Current primary diagnostic and treatment options used
- Risk factors and the most common clinical trial challenges
- Overcoming trial challenges such as choosing the correct comparator drug, using liquid biopsies where available, and the possibility of emergent brain radiation involvement
“Worldwide, there were an estimated 2.2 million newly diagnosed patients in 2020.’’
Lung cancer is one of the diseases that will never vanish from the radar of physicians, scientists, and society. However, there have been significant advances in our understanding and treatment of this disease over the past century, particularly for non-small cell lung cancer (NSCLC). In this white paper, we review the primary diagnostic and treatment options used today, the current trends, and their implications on the design and conduct of NSCLC clinical trials.
In 1912, the American physician Dr. Isaac Adler reported a total of 374 cases of lung cancer described in the literature worldwide. In 2021, an estimated 235,000 people in the United States alone were diagnosed with lung cancer. Worldwide, there were an estimated 2.2 million newly diagnosed patients in 2020.
There are two major histologic subtypes of lung cancer: non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. SCLC accounts for between 10% and 15% of lung cancers, while pulmonary carcinoid tumors are uncommon neuroendocrine epithelial malignancies accounting for less than 1% of all lung cancers. NSCLC and SCLC differ significantly in the pace of development, staging classification, treatment options, and survival perspectives. Our paper will talk about NSCLC as the most prevalent type of lung cancer.